Lupin Overview
- Year Founded
-
1968
- Status
-
Public
- Employees
-
19,862
- Stock Symbol
-
500257
- Investments
-
34
- Share Price
-
$24.38
- (As of Friday Closing)
Lupin General Information
Description
Lupin Ltd is a specialty and generic drug manufacturing company. The company produces, develops, and markets branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) globally. It has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, GastroIntestinal, and other drug therapy segments. The operations of the company are limited to the segments, namely pharmaceuticals which derives key revenue, and others. It also maintains a pipeline in high-barrier markets such as Inhalation, Biosimilars, and Complex Injectables. The vast majority of the company's sales are generated in the United States, followed by India, and other countries.
Contact Information
Website
www.lupin.comCorporate Office
- 3rd Floor, Kalpataru Inspire
- Off. Western Expressway Highway, Santacruz (East)
- Mumbai, 400055
- India
Corporate Office
- 3rd Floor, Kalpataru Inspire
- Off. Western Expressway Highway, Santacruz (East)
- Mumbai, 400055
- India
Lupin Stock Performance
As of 17-Jan-2025, Lupin’s stock price is $24.38. Its current market cap is $11.1B with 456M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $24.38 | $24.29 | $16.98 - $27.92 | $11.1B | 456M | 26.4K | $0.69 |
Lupin Financials Summary
As of 30-Sep-2024, Lupin has a trailing 12-month revenue of $2.52B.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2024 31-Mar-2024 | FY 2023 31-Mar-2023 | FY 2022 31-Mar-2022 |
|---|---|---|---|---|
| EV | 12,032,708 | 9,031,601 | 3,936,810 | 4,461,529 |
| Revenue | 2,517,095 | 2,374,360 | 2,026,204 | 2,173,309 |
| EBITDA | 540,299 | 436,252 | 219,881 | (64,324) |
| Net Income | 315,020 | 231,257 | 53,561 | (205,085) |
| Total Assets | 3,043,825 | 2,877,584 | 2,796,060 | 2,877,715 |
| Total Debt | 411,207 | 350,359 | 553,163 | 548,394 |
Lupin Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Lupin Comparisons
Industry
Financing
Details
Lupin Competitors (40)
One of Lupin’s 40 competitors is Cipla, a Corporation company based in Mumbai, India.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Cipla | Corporation | Mumbai, India | ||||
| Torrent Pharmaceuticals | Corporation | Ahmedabad, India | ||||
| Ajanta Pharma | Corporation | Mumbai, India | ||||
| Biocon | Formerly PE-Backed | Bengaluru, India | ||||
| Jubilant Pharmova | Corporation | Noida, India |
Lupin Patents
Lupin Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20240350480-A1 | Stable pharmaceutical composition of methylnaltrexone for an oral administration | Pending | 18-Apr-2023 | ||
| CA-224451-S | Tray | Active | 24-Mar-2023 | ||
| US-20240123169-A1 | Breath actuated inhaler | Pending | 17-Oct-2022 | ||
| US-20230149635-A1 | Applicator for implant insertion | Pending | 12-Nov-2021 | ||
| CA-3238071-A1 | Applicator for implant insertion | Pending | 12-Nov-2021 | A61M5/3202 |
Lupin Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Lupin Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Lupin Investments & Acquisitions (34)
Lupin’s most recent deal was a Corporate Asset Purchase with Eli Lilly and Company (Huminsulin Product Portfolio). The deal was made on 30-Dec-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Eli Lilly and Company (Huminsulin Product Portfolio) | 30-Dec-2024 | Corporate Asset Purchase | Buildings and Property | ||
| Boehringer Ingelheim (Anti-Diabetes Trademarks GIBTULIO, GIBTULIO MET and AJADUO) | 13-Dec-2024 | Corporate Asset Purchase | Buildings and Property | ||
| Sunsure Solarpark Seventeen | 11-Sep-2024 | Secondary Transaction - Private | Automotive | ||
| Sanofi (2 Pharmaceutical Brands) | 31-Mar-2024 | Corporate Asset Purchase | Buildings and Property | ||
| Menarini (Five Legacy Brands Located in Florence, Italy) | 22-Sep-2023 | Corporate Asset Purchase | Buildings and Property |
Lupin ESG
Risk Overview
Risk Rating
Updated May, 31, 2024
32.44 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,104
Rank
Percentile
Pharmaceuticals
Industry
of 851
Rank
Percentile
Pharmaceuticals
Subindustry
of 424
Rank
Percentile
Lupin Exits (1)
Lupin’s most recent exit was on 10-Oct-2007 from Kyowa Pharmaceutical. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Kyowa Pharmaceutical | 10-Oct-2007 | Completed |
|
Affiliates
Subsidiaries (6)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Generic Health | Box Hill, Australia | 2004 | |
| Nanomi | Oldenzaal, Netherlands | 2004 | |
| MyDynamics | Cape Town, South Africa | 2001 | |
| Multicare Pharmaceuticals Philippines | Makati City, Philippines | 1998 | |
| Medquímica Indústria Farmacêutica | Juiz de Fora, Brazil | 1975 |
Lupin FAQs
-
When was Lupin founded?
Lupin was founded in 1968.
-
Where is Lupin headquartered?
Lupin is headquartered in Mumbai, India.
-
What is the size of Lupin?
Lupin has 19,862 total employees.
-
What industry is Lupin in?
Lupin’s primary industry is Pharmaceuticals.
-
Is Lupin a private or public company?
Lupin is a Public company.
-
What is Lupin’s stock symbol?
The ticker symbol for Lupin is 500257.
-
What is the current stock price of Lupin?
As of 17-Jan-2025 the stock price of Lupin is $24.38.
-
What is the current market cap of Lupin?
The current market capitalization of Lupin is $11.1B.
-
What is Lupin’s current revenue?
The trailing twelve month revenue for Lupin is $2.52B.
-
Who are Lupin’s competitors?
Cipla, Torrent Pharmaceuticals, Ajanta Pharma, Biocon, and Jubilant Pharmova are some of the 40 competitors of Lupin.
-
What is Lupin’s annual earnings per share (EPS)?
Lupin’s EPS for 12 months was $0.69.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
